Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147
      QxMD      Google Scholar   
Citation:
Clin Colorectal Cancer vol 13 (2) 100-109
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
SDC:
No
Book Volume:
3
Parents:
576   2522  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
CA37377, CA-37404, N01 CA032102, U10 CA077202, CA077202, U10 CA021115, U10 CA012027, U10 CA180835, CA12027, U10 CA031946, CA-14028, U10 CA037404, U24 CA114740, U10 CA014028, CA-114740, CA-35103, CA-25224, U10 CA180850, U10 CA037403, U10 CA035272, CA49957, CA-35113, CA-32102, U10 CA032102, U10 CA035113, U10 CA180790, P30 CA015083, P30 CA016058, U10 CA180820, CA-35272, U10 CA049957, CA21115, U10 CA025224, U10 CA180888, CA31946, U10 CA037377, U10 CA035103  
Corr. Author:
 
Authors:
                                           
Networks:
 
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Adjuvant therapy, Disease free survival, Overall survival, Response rate